European equities traded in the US as American depositary receipts were heading higher late Wednesday morning, rising 0.67% to 1,636.27 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biopharmaceutical companies DBV Technologies (DBVT) and Cellectis (CLLS), which climbed 14% and 6.8%, respectively. They were followed by pharmaceutical company Novo Nordisk (NVO) and brewing company Anheuser-Busch InBev (BUD), which advanced 3.8% and 1.8%, respectively.

The decliners from continental Europe were led by biotech firm Evaxion (EVAX) and semiconductor company Sequans Communications (SQNS), which fell 3.8% and 2.1%, respectively. They were followed by internet advertising firm Criteo (CRTO) and medical device maker EDAP TMS (EDAP), which were down 1.9% each.

From the UK and Ireland, the gainers were led by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and lender HSBC (HSBC), which rose 33% and 4.1%, respectively. They were followed by biopharmaceutical company Bicycle Therapeutics (BCYC) and educational publisher Pearson (PSO), which were up 3.7% and 3.5%, respectively.

The decliners from the UK and Ireland were led by biotech company Trinity Biotech (TRIB) and biopharmaceutical company Amarin (AMRN), which dropped 2.5% and 1.6%, respectively. They were followed by biopharmaceutical companies NuCana (NCNA) and Akari Therapeutics (AKTX), which lost 1.2% and 0.3%, respectively.